ATE481102T1 - Beclomethasondipropionat und prednison zur verminderung der sterblichkeit in zusammenhang mit der graft-versus-host-reaktion - Google Patents

Beclomethasondipropionat und prednison zur verminderung der sterblichkeit in zusammenhang mit der graft-versus-host-reaktion

Info

Publication number
ATE481102T1
ATE481102T1 AT05856121T AT05856121T ATE481102T1 AT E481102 T1 ATE481102 T1 AT E481102T1 AT 05856121 T AT05856121 T AT 05856121T AT 05856121 T AT05856121 T AT 05856121T AT E481102 T1 ATE481102 T1 AT E481102T1
Authority
AT
Austria
Prior art keywords
days
prednisone
mortality associated
versus host
graft versus
Prior art date
Application number
AT05856121T
Other languages
German (de)
English (en)
Inventor
George B Mcdonald
Nicholas Stergis
Steve Kanzer
Original Assignee
Soligenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soligenix Inc filed Critical Soligenix Inc
Application granted granted Critical
Publication of ATE481102T1 publication Critical patent/ATE481102T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05856121T 2004-12-30 2005-12-30 Beclomethasondipropionat und prednison zur verminderung der sterblichkeit in zusammenhang mit der graft-versus-host-reaktion ATE481102T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64017804P 2004-12-30 2004-12-30
PCT/US2005/047666 WO2006072093A2 (en) 2004-12-30 2005-12-30 Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone

Publications (1)

Publication Number Publication Date
ATE481102T1 true ATE481102T1 (de) 2010-10-15

Family

ID=36615583

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05856121T ATE481102T1 (de) 2004-12-30 2005-12-30 Beclomethasondipropionat und prednison zur verminderung der sterblichkeit in zusammenhang mit der graft-versus-host-reaktion

Country Status (13)

Country Link
US (1) US20060252735A1 (https=)
EP (1) EP1830857B1 (https=)
JP (1) JP2008526773A (https=)
KR (1) KR20070089701A (https=)
CN (2) CN101060848B (https=)
AT (1) ATE481102T1 (https=)
AU (1) AU2005321826B2 (https=)
CA (1) CA2583244A1 (https=)
DE (1) DE602005023655D1 (https=)
DK (1) DK1830857T3 (https=)
IL (1) IL182462A0 (https=)
NZ (1) NZ554326A (https=)
WO (1) WO2006072093A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090143328A1 (en) * 2001-08-13 2009-06-04 Mcdonald George Method of Treating Cancer by Administration of Topical Active Corticosteroids
SG10201704531XA (en) * 2008-12-08 2017-07-28 Soligenix Inc Topically active steroids for use in radiation and chemotherapeutics injury
US20170209447A1 (en) * 2014-08-07 2017-07-27 Nitor Therapeutics Use of PNP Inhibitor to Treat Relapse of Malignancy after Hematopoietic Stem Cell Transplant
CN106236736A (zh) * 2016-09-26 2016-12-21 安徽省逸欣铭医药科技有限公司 二丙酸倍氯米松肠溶缓释片及其制备方法
EP4073100A4 (en) 2019-12-09 2024-02-14 Syndax Pharmaceuticals, Inc. ANTIBODIES FOR TREATING CHRONIC GRAFT VERSUS HOST DISEASE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US5747474A (en) * 1996-07-29 1998-05-05 Immune Modulation, Inc. Immunosuppression by administration of N6,N6 -disubstituted cAMP's, analogues thereof, and related nucleosides
US6096731A (en) * 1998-06-24 2000-08-01 Institute For Drug Research, Inc. Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation
US20020086857A1 (en) * 2000-09-15 2002-07-04 Mcdonald George B. Method of long-term treatment of graft-versus-host disease using topical active corticosterioids
AU2002254205B2 (en) * 2001-03-15 2007-05-10 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
US20030032631A1 (en) 2001-08-13 2003-02-13 Mcdonald George B. Method of treatment of cancer by controlling graft-versus-leukemia using topical active corticosteriods
JP4014912B2 (ja) * 2001-09-28 2007-11-28 株式会社ルネサステクノロジ 半導体装置

Also Published As

Publication number Publication date
WO2006072093A3 (en) 2007-03-22
CN101060848A (zh) 2007-10-24
EP1830857B1 (en) 2010-09-15
EP1830857A4 (en) 2008-02-27
KR20070089701A (ko) 2007-08-31
DK1830857T3 (da) 2011-02-07
EP1830857A2 (en) 2007-09-12
NZ554326A (en) 2010-10-29
AU2005321826A1 (en) 2006-07-06
CA2583244A1 (en) 2006-07-06
JP2008526773A (ja) 2008-07-24
AU2005321826B2 (en) 2012-03-15
US20060252735A1 (en) 2006-11-09
WO2006072093A2 (en) 2006-07-06
DE602005023655D1 (de) 2010-10-28
IL182462A0 (en) 2008-04-13
CN101060848B (zh) 2011-06-22
CN102218070A (zh) 2011-10-19

Similar Documents

Publication Publication Date Title
Barrowman et al. Oral rehabilitation with dental implants after cancer treatment
Zen Filho et al. Viability of dental implants in head and neck irradiated patients: a systematic review
Kamal et al. A comparative clinical study between concentrated growth factor and low-level laser therapy in the management of dry socket
WO2005034843A3 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
McCaul Pharmacologic modalities in the treatment of osteoradionecrosis of the jaw
TW200612987A (en) Combination treatment for non-hematologic malignancies
MXPA05008617A (es) Usos de anticuerpos anti-receptor del factor de crecimiento semejante a la insulina i.
EP2465923A3 (en) Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
MX2010002410A (es) Metodo para proveer los beneficios de energia, alivio del estres y mejora del estado de animo, que comprende administrar una composicion que comprende colecalciferol y un extracto de te.
WO2006014159A3 (en) Methods of using regenerative cells in the treatment of musculoskeletal disorders
Bassetto et al. Hyperbaric oxygen therapy in Plastic Surgery practice: case series and literature overview
IL182462A0 (en) Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone
PL1778833T3 (pl) Sposoby stosowania komórek regeneracyjnych w celu przyspieszania gojenia się ran
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
MX2022016410A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos.
WO2021262562A3 (en) Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof
Efremov et al. The immunosuppressive effects of volatile versus intravenous anesthesia combined with epidural analgesia on kidney cancer: a pilot randomized controlled trial
Anzalone et al. Oroantral communication as an osteotome sinus elevation complication
MY148085A (en) Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone
Kumhyr et al. Changes in immunological parameters in patients treated using direct and indirect restorations of the hard tissues of the anterior teeth in combination with an antioxidant
Boer et al. Four‐day quadruple therapy as a routine treatment for Helicobacter pylori infection
Ro et al. Effect of polydeoxyribonucleotide on human periodontal ligament cells as a storage medium for avulsed tooth
Kaibuchi et al. Cell therapy for medication-related osteonecrosis of the jaw: update on treatment strategies
Bhat et al. Therapeutic modalities in the management of COVID-19: a worldwide landscape

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties